CG Oncology (CGON) Earnings Analysis

CG Oncology (CGON) next reports earnings on 2026-08-07, consensus EPS -0.7 USD. Last quarter (2026-05-08) it missed with EPS -0.71 USD vs -0.58 USD est (-22.4%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -29.62.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CGON next report earnings?

Next earnings date2026-08-07
Consensus EPS estimate-0.7 USD
Revenue estimate0.00B

CGON earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-08-0.71 USD-0.58 USD-22.4%Miss
2026-02-27-0.51 USD-0.61 USD+16.4%Beat
2025-11-14-0.57 USD-0.55902 USD-2%Miss
2025-08-08-0.54 USD-0.49 USD-10.2%Miss

Beat rate: 1/4 (25%) over reported quarters with consensus data.

CGON valuation and analyst view

Trailing P/E-29.62
Trailing EPS-2.20952 USD
Price / book5.37
Dividend yield0.00%
Market cap6.21B
Analyst consensusBuy (10 buy / 0 hold / 0 sell)
Avg price target80.5 USD

Related research pages

Frequently asked questions

When is CG Oncology (CGON)'s next earnings date?

CG Oncology is next scheduled to report on 2026-08-07, with a consensus EPS estimate of -0.7 USD and revenue estimate of 0.00B.

Did CGON beat earnings last quarter?

In its 2026-05-08 report, CGON posted EPS of -0.71 USD versus a -0.58 USD estimate — a miss of 22.4%.

What is CGON's earnings track record?

Over the last 4 reported quarters with consensus data, CGON beat estimates 1 times (25%).

What is CGON's current P/E ratio and EPS?

CGON trades at a trailing P/E of -29.62 on trailing EPS of -2.209515946045051 USD.

What do analysts rate CGON?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 80.5 USD.